Microbiome NewsIn September 2024, Flore Inc. — a personalized-probiotics company formerly known as Sun Genomics — launched what it described as the first line of probiotics formulated specifically for neurodiversity. The announcement was carried across nutrition and trade outlets including Globe Newswire, Nutraceuticals World, Nutrition Insight and Vitafoods Insights.
The line sits squarely within the broader gut–brain-axis thesis — the idea that the gut microbiome participates in signalling to the central nervous system. Flore, whose core product is a formula built from an individual’s sequenced stool, framed the launch as an extension of that personalized approach to a neurodivergent audience.
What to keep in view
The products are positioned as dietary supplements, not treatments. And the relevant scientific caveat is the same one that applies to every gut–brain consumer claim: while the preclinical literature is substantial, rigorous human evidence that probiotics modify neurodevelopmental or mood outcomes remains early-stage. The launch is a notable commercial and positioning move; it is not, on its own, clinical proof.
Coverage of the company’s products on this site is reported on its own merits, like that of any other company in the field. Details of the line are at flore.com.